Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment.

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

2002 • 5,471 citations

Culture, Illness, and Care

1978 • 2,827 citations

Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics

1999 • 2,458 citations

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

2002 • 1,592 citations

Management of Pain in Elderly Patients With Cancer

1998 • 1,167 citations

Inequality in Quality

2000 • 1,160 citations

Racial Differences in the Treatment of Early-Stage Lung Cancer

1999 • 991 citations

Genes, peoples, and languages

2000 • 768 citations

Variations in the Care of HIV-Infected Adults in the United States

1999 • 730 citations

Molecular Basis of Ethnic Differences in Drug Disposition and Response

2001 • 595 citations

Lesser Response to Angiotensin-Converting–Enzyme Inhibitor Therapy in Black as Compared with White Patients with Left Ventricular Dysfunction

2001 • 558 citations

MOLECULAR MECHANISMS OF GENETIC POLYMORPHISMS OF DRUG METABOLISM

1997 • 540 citations

“We Don't Carry That” — Failure of Pharmacies in Predominantly Nonwhite Neighborhoods to Stock Opioid Analgesics

2000 • 450 citations

Racial Differences in the Use of Drug Therapy for HIV Disease in an Urban Community

1994 • 372 citations

Race and the Response to Adrenergic Blockade with Carvedilol in Patients with Chronic Heart Failure

2001 • 300 citations

High Polymorphism at the Human Melanocortin 1 Receptor Locus

1999 • 289 citations

A Comparison of the Efficacy and Safety of a β-Blocker, a Calcium Channel Blocker, and a Converting Enzyme Inhibitor in Hypertensive Blacks

1990 • 263 citations

Ethnic Differences in Drug Metabolism

1982 • 229 citations

HLA-B38, DR4, DQw3 and Clozapine-Induced Agranulocytosis in Jewish Patients With Schizophrenia

1990 • 211 citations

Pharmacogenetics and psychopharmacotherapy

2000 • 197 citations

Regional and Racial Differences in Response to Antihypertensive Medication Use in a Randomized Controlled Trial of Men With Hypertension in the United States

2000 • 170 citations

Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency.

1997 • 162 citations

Attenuation of Isoproterenol-Mediated Vasodilatation in Blacks

1995 • 161 citations

Racial Differences in Cardiac Revascularization Rates: Does “Overuse” Explain Higher Rates among White Patients?

2001 • 156 citations

Ethnic Differences in Drug Disposition and Responsiveness

1991 • 154 citations

Genetic Variation as a Guide to Drug Development

1998 • 143 citations

Genomic Views of Human History

1999 • 113 citations

Amiloride, a Specific Drug for Hypertension in Black People With T594M Variant?

2002 • 94 citations

Populations and genetic polymorphisms.

1999 • 85 citations

Pharmacogenetics

1999 • 80 citations

Tumor Necrosis Factor Constellation Polymorphism and Clozapine-Induced Agranulocytosis in Two Different Ethnic Groups

1997 • 72 citations

Effect of race on hypertension and antihypertensive therapy

2000 • 71 citations

Apolipoprotein E Polymorphisms and Concentration in Chronic Diseases and Drug Responses

2000 • 66 citations

The management of hypertensive disease in Black patients

1999 • 65 citations

Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension

2001 • 63 citations

Racial Disparities in Service Use among Medicaid Beneficiaries after Mandatory Enrollment in Managed Care: A Difference-in-Differences Approach

2001 • 60 citations

Clinical issues in the pharmacotherapy of African-Americans.

1996 • 53 citations

Psychopharmacologic considerations in the treatment of black American populations.

1991 • 44 citations

Using Angiotensin Converting Enzyme Inhibitors in African-American Hypertensives: A New Approach to Treating Hypertension and Preventing Target-Organ Damage

2000 • 40 citations

Ethnic Differences in Drug Metabolism

2000 • 36 citations

Antihypertensive and metabolic effects of a new converting enzyme inhibitor, enalapril

1983 • 34 citations

Phototoxicity to benoxaprofen.

1982 • 30 citations

Combined α/β-blockade versus β1-selective blockade in essential hypertension in black and white patients

1990 • 29 citations

Use of β ‐ Adrenergic Receptor Blockers in Blacks

1996 • 26 citations

Skin Pigmentation as a Predictor of Minimal Phototoxic Dose After Oral Methoxsalen

1994 • 20 citations

Comparison of the antihypertensive effect of enalapril and propranolol in black South Africans.

1985 • 15 citations

Drug treatment considerations for the hypertensive black patient.

1988 • 14 citations

Labetalol compared with propranolol in the treatment of black hypertensive patients.

1987 • 14 citations

Analysis of Effects of Ultraviolet B Radiation on Induction of Primary Allergic Reactions

1992 • 12 citations

Pharmacoanthropology: outline, problems, and the nature of case histories.

1984 • 11 citations

The influence of host factors on drug response. I. Ethnic background.

1979 • 3 citations